跳转至内容
Merck

Y0000779

氯噻酮

European Pharmacopoeia (EP) Reference Standard

别名:

Chlorthalidone

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C14H11ClN2O4S
CAS号:
分子量:
338.77
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23

InChI

1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)

InChI 密鑰

JIVPVXMEBJLZRO-UHFFFAOYSA-N

基因資訊

human ... SLC12A3(6559)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Chlortalidone for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

George C Roush et al.
Current hypertension reports, 15(5), 514-521 (2013-07-11)
How chlorthalidone (CTDN) reduces risk for cardiovascular events (CVEs) can be considered in light of its ability to lower blood pressure (BP) and its non-BP related, pleiotropic effects. The mechanism by which CTDN lowers BP is unclear but may include
Kimberly M Neff et al.
Cardiology in review, 18(1), 51-56 (2009-12-17)
Thiazide diuretics are a mainstay for the treatment of hypertension. Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure. This is despite several clinical trials that
Jerrica E Shuster et al.
Vascular health and risk management, 8, 381-387 (2012-06-30)
Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing
David S Kountz et al.
Postgraduate medicine, 124(1), 60-66 (2012-02-09)
Chlorthalidone's safety and efficacy in the management of hypertension has been demonstrated in landmark trials. Despite understanding the effects of thiazides on urinary sodium excretion and intravascular volume, the exact mechanism of their antihypertensive effects is not clearly understood. Common
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
Nitin Khosla et al.
Journal of clinical hypertension (Greenwich, Conn.), 7(6), 354-356 (2005-08-10)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门